Covance Becomes Exclusive Provider of Neuroscience Gold Standard Antibodies 6E10 and 4G8 for Alzheimer's Disease, 3F4 for Prion Diseases
— Covance now offers the industry's most comprehensive list of neuroimmunology tools —
Princeton, New Jersey, January 22, 2007 — today announced that it will now be the exclusive provider of neuroscience gold standard antibodies beta amyloid 6E10 and 4G8 for Alzheimer's disease and 3F4 for prion disease research.
These antibodies head up the most comprehensive list of neuroimmunology tools available to the academic, biotech, and pharmaceutical industries. With the recent acquisition of Signet Laboratories, Covance has strengthened its position as a supplier of antibodies in the fields of Alzheimer's, Parkinson's and other neurodegenerative diseases and now offers a portfolio of more than 800 innovative antibody products.
Alzheimer's disease is characterized pathologically by the formation of extracellular amyloid plaques that have been shown to be deposited in CNS of patients with Alzheimer's disease and Down's syndrome. These plaques are predominantly composed of beta amyloid protein, which is derived from the proteolytic processing of amyloid precursor protein. The clones 4G8 and 6E10 are both widely recognized and used among top researchers in the field.
Prion diseases, or Transmissible Spongiform Encephalopathies (TSE), are degenerative diseases of the nervous system caused by transmissible particles that contain a pathogenic isoform of the prion protein, a normal constituent of cell membranes. These fatal diseases can affect bovine (BSE/Mad Cow), sheep (Scrapie), deer and elk (CWD), and humans (vCJD).
Although cross-species transmission of prion diseases seems to be limited by a "species barrier," the occurrence of bovine spongiform encephalopathy (BSE) and its transmission to humans indicate that animal prion diseases can pose a significant public health risk.
For business inquiries, contact Covance Research Products at 1-800-223-0796 or visit www.CRPinc.com.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in more than 20 countries, and more than 8,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. Covance and the Covance logo are registered service marks of Covance in the United States and other countries.